NEW YORK (GenomeWeb News) – Exagen Diagnostics this week said in a regulatory filing that it raised a little more than $5 million in an equity financing round.

A spokesperson for the Albuquerque, NM-based firm declined to comment on the raise. In its document filed with the US Securities and Exchange Commission, Exagen did not disclose the investors or say how the proceeds would be used.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.